

Nectar Lifesciences Ltd.



Ref.: NLL/CS/2017-94

Date: 05-07-2017

1. National Stock Exchange of India Limited
'G' Block, Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051.
2. BSE Limited
Phiroze Jeejeebhoy Towers, Dalal Street,
Mumbai – 400 001.

SCORES Registration ID: n00069.

Subject: Quarterly Statements of Investor Complaints

Sir,

Pursuant to Regulation 13(3) of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Statement of Investor Complaints for the Quarter ended June 30, 2017 is as under:

Particulars	Number of Complaints
Pending at the Beginning of the Quarter	Nil
Received during the Quarter	5
Disposed off during the Quarter	5
Remaining unsolved at the end of the Quarter	Nil

You are requested to kindly take the above information on record.

Thanking you,

Yours faithfully,
For **Nectar Lifesciences Limited**


(Sukhwinder Singh)
Company Secretary

Corporate Office : S.C.O. 38-39, Sector 9-D, Chandigarh-160 009 (India) Tel. : +91-172-3047777 Fax : +91-172-3047755
E-mail : sales@neclife.com Website : www.neclife.com
CIN : L24232 PB1995 PLC 016664

Regd. Office & Works : Vill. Saidpura, Teh. Dera Bassi, Distt. Mohali (Punjab) Near Chandigarh (INDIA)
Tel. : +91-1762-308000, 308001 Fax : +91-1762-281187, 308135